RESUMO
Methotrexate is a dihydrofolate reductase inhibitor that interferes with DNA synthesis, DNA repair, and cellular replication. We present the first adult case of a patient who received intravenous contrast prior to administration of high-dose methotrexate, who subsequently experienced delayed methotrexate clearance and renal impairment necessitating the use of glucarpidase. This case displays a possible correlation between intravenous radiographic contrast administration and resulting toxicity due to delayed methotrexate clearance.
Assuntos
Antimetabólitos Antineoplásicos/efeitos adversos , Meios de Contraste/efeitos adversos , Rim/efeitos dos fármacos , Metotrexato/efeitos adversos , gama-Glutamil Hidrolase/uso terapêutico , Interações Medicamentosas , Feminino , Humanos , Infusões Intravenosas , Metotrexato/farmacocinética , Pessoa de Meia-Idade , Tomografia Computadorizada por Raios XRESUMO
Immunotherapy is an expanding area of cancer treatment with significant promise. Despite their efficacy, checkpoint inhibitors are associated with a number of immune-related adverse events; here, we described thrombocytopenia secondary todurvalumab.